Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07595549 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

StatusRecruiting
PhasePhase 3
SponsorPfizer
Started2026-06-10
View on ClinicalTrials.gov ↗

Amendment history

2026-09-03
minor
Study Status, Contacts/Locations v6
Trial sites expanded: 50 → 58 locations
Trial sites expanded: 38 → 50 locations
2026-08-14
minor
Study Status, Contacts/Locations v5
Trial sites expanded: 25 → 38 locations
2026-07-21
minor
Study Status, Contacts/Locations v4
Trial sites expanded: 19 → 25 locations
2026-07-07
minor
Study Status, Contacts/Locations v3
Trial sites expanded: 9 → 19 locations
2026-06-18
notable
Study Status, Outcome Measures, Contacts/Locations v2
Recruitment opened
Trial sites expanded: 0 → 9 locations
Start dateestimated 2026-06-30→confirmed 2026-06-10
Secondary endpoints36 entries, revised
Percentage of Participants with a waist-to-height ratio of <0.553
2026-05-26
minor
Study Status v1
Start date2026-06-02→2026-06-30
2026-05-12
minor
Original filing
431 trials monitored
See 32 trials at risk
3,523 trials monitored
See 133 trials at risk
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe. People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.
Trial Details
NCT Number NCT07595549
Lead Sponsor Pfizer
Conditions Obesity, Overweight and/or Obesity, Overweight
Enrollment 954 participants
Start Date 2026-06-10
Primary Completion 2028-05-04 (estimated)
Study Completion 2028-06-21 (estimated)
Updated on ClinicalTrials.gov 2026-09-28